Enoki & Immunity
Butyrate rose in enoki-fed rats
Ye et al. (2020) gave rats a purified Flammulina velutipes polysaccharide for two weeks and found significantly higher caecal butyric and isobutyric acid alongside more beneficial gut bacteria. Butyrate is the short-chain fatty acid that fuels colon cells and maintains the gut barrier.
Ye et al., 2020
Bacteroides
SCFA-producing genus that increased in enoki-treated mice (Liang et al., 2022)
Spleen + heart
remote organs where enoki-driven changes have been detected (Liang 2022; Hao 2021)
No trials
four rodent studies and one ex vivo human-stool experiment; no human clinical trial
Ye et al., 2020
View as image ↗Most of the immune research on enoki mushrooms focuses on what happens when polysaccharides meet macrophages directly: receptor binding, NF-κB/MAPK signaling, cytokine release. That direct pathway is covered in detail in the companion article on enoki polysaccharides and immune cell activation. But there is a second pathway, and it runs through the gut. Enoki polysaccharides that pass through the small intestine undigested reach the colon, where gut bacteria ferment them. Short-chain fatty acids (SCFAs) are a principal byproduct of that fermentation. SCFAs are not metabolic waste. They fuel the cells lining the colon, help maintain the intestinal barrier, and act as signaling molecules that influence immune tone.
This article covers that second pathway and the enoki mushroom gut immune system connection specifically: five studies published between 2020 and 2023 that documented the gut microbiota shifts, the SCFA changes, and the downstream signals detected in organs outside the gut. It also covers where those studies disagree, which turns out to matter. For the full species context, see What Is Enoki Mushroom?.
Key Takeaways
- Ye et al. (2020) tested one purified F. velutipes polysaccharide two ways at once: it activated macrophages in cell culture and, given orally to rats for two weeks, raised caecal butyric and isobutyric acid while increasing beneficial gut bacteria
- Hao et al. (2021) fed C57BL/6 mice enoki polysaccharide for 28 days and found taller intestinal villi and a higher villus-to-crypt ratio, with Firmicutes rising and Bacteroidetes slightly falling
- Liang et al. (2022) is the study that actually links enoki to Bacteroides and SCFAs: in immunosuppressed mice it raised total SCFA content and the abundance of SCFA-producing Bacteroides and Alloprevotella, while raising thymus and spleen indices
- Su et al. (2023) fermented enoki polysaccharide with human stool bacteria in vitro and saw Bifidobacteriaceae and Bacteroidaceae increase while Lachnospiraceae and Enterococcaceae decreased
- The studies do not agree on the direction of Bacteroidetes-lineage bacteria, and no study has quantified propionate or acetate changes from enoki polysaccharide
- Four of the five studies used mice or rats and one used human stool bacteria outside the body; no human clinical trial has tested enoki polysaccharides for gut-immune outcomes
Why the Gut Is the Body's Largest Immune Organ
A large share of the body's immune cells, commonly estimated at around 70%, sit in and around the intestine in a tissue layer called gut-associated lymphoid tissue (GALT). GALT samples what passes through the intestine and helps calibrate immune tolerance: what to attack, what to ignore. The microbiome, the collection of bacteria, fungi, and viruses living in the gut, shapes that calibration continuously. This is standard immunology background rather than a finding from any enoki study, and it is the reason a change in gut bacteria can plausibly register as a change in immune function.
Fiber and polysaccharides that resist digestion in the small intestine are the primary food source for colonic bacteria. The specific structure of a polysaccharide determines which bacteria are equipped to process it, and therefore which populations it selectively feeds. That selectivity is the prebiotic mechanism, and it is where the gut-immune pathway for enoki polysaccharides begins.
Five Studies · One Chain
What Each Enoki Gut-Immune Study Actually Reports
The gut-mediated case is built from five preclinical papers. Each link below is tagged with the system it was run in and the finding the paper itself states. Four are rodent studies; one is human gut bacteria fermented outside the body. None is a human trial.
- 1
Two effects, one molecule
Ye et al., 2020Reported signature
butyrate ↑ · isobutyrate ↑
A characterised polysaccharide (FVP2, 18.3 kD) raised nitric oxide, TNF-α and IL-6 in RAW 264.7 macrophages, and separately — given to rats for two weeks — significantly raised caecal butyric and isobutyric acid with more beneficial microbiota. Two systems, one compound; not a demonstrated causal chain between them.
RodentRef 1 - 2
Gut structure changes
Hao et al., 2021Reported signature
villus height ↑ · V/C ↑
Across a 28-day feed in C57BL/6 mice, intestinal sections showed taller villi and a higher villus-to-crypt ratio. 16S sequencing found Firmicutes up and Bacteroidetes slightly down. No SCFAs were measured, and the authors did not label the shifts beneficial or pathogenic.
RodentRef 2 - 3
SCFAs and immune organs move together
Liang et al., 2022Reported signature
SCFA ↑ · Bacteroides ↑
In immunosuppressed mice, total SCFA content rose along with the SCFA producers Bacteroides and Alloprevotella. Thymus and spleen indices rose, IL-2/IL-4 rose, IL-6/TNF-α fell, and proteomics flagged TFRC and RSAD2. The comparison is against a suppressed model, so this is restoration, not enhancement.
RodentRef 3 - 4
Human bacteria, no host
Su et al., 2023Reported signature
Bifidobacteriaceae ↑ · Bacteroidaceae ↑
Enoki polysaccharide fermented with human faecal inoculum increased Bifidobacteriaceae and Bacteroidaceae and decreased Lachnospiraceae and Enterococcaceae. Metabolomics pointed to glycerophospholipid, linoleic acid and unsaturated fatty acid pathways — not SCFAs. Closest to human data, but a flask has no immune system.
Human stool, in vitroRef 4 - 5
Signal detected far from the gut
Hao et al., 2021 (repertoire)Reported signature
41 V-J pairs · 525 heart genes
Alongside regulating colonic microbiota, enoki polysaccharide shifted T-cell receptor gene usage (TRBV1, TRBJ1-6, TRBJ1-5; 41 V-J pairs differed) and changed 525 genes in heart tissue. Repertoire shift is a deeper immune readout than a cytokine value — but the route from gut to remote organ was not traced.
RodentRef 5
No figure for propionate or acetate appears in this chain because no study in it quantifies either one for enoki polysaccharide. Only butyrate/isobutyrate (Ref 1) and total SCFA content (Ref 3) have been measured.
Source: Ye et al. (2020); Hao et al. (2021, gut health); Liang et al. (2022); Su et al. (2023); Hao et al. (2021, immune repertoire)
The Study That Found Both Effects at Once
Ye and colleagues (2020) isolated a novel polysaccharide from Flammulina velutipes, designated FVP2, and ran it through two experimental systems in the same paper.[1] FVP2 has a molecular weight of 18.3 kD and is built mainly from glucose (60.66%), galactose (19.96%), and mannose (19.38%).
In the first arm, they applied FVP2 to RAW 264.7 murine macrophage cells and measured immune activation. The polysaccharide significantly upregulated nitric oxide, TNF-α, and IL-6. Those are markers of macrophages shifting into an activated, pro-inflammatory state, which is the expected in vitro response to a fungal polysaccharide.
In the second arm, they administered FVP2 intragastrically to rats for two weeks. Compared with controls, the treated rats showed significantly higher concentrations of two caecal short-chain fatty acids, butyric acid and isobutyric acid, and a significantly greater abundance of beneficial microbiota. The authors concluded that FVP2 could improve intestinal barrier function and help maintain mucosal integrity.
The value of the Ye 2020 design is that it rules out one mechanism being an artifact of the other. Direct macrophage activation in cell culture happens without a gut; caecal SCFA changes in live rats happen without cell-culture conditions. The same characterized compound produced both, in independent systems, in one study. It is worth being precise about what this does not show: the study did not demonstrate that the macrophage activation in the dish was caused by the gut changes in the rat, or vice versa. It shows two effects of one molecule, not a causal chain between them.
What Happens to Gut Bacteria When Enoki Polysaccharides Arrive
Hao and colleagues (2021) ran a 28-day feeding experiment in healthy C57BL/6 mice.[2] The clearest result was structural: intestinal tissue sections from the treated group showed greater villus height and a higher villus-height-to-crypt-depth ratio. Villus height and the V/C ratio are standard readouts of absorptive surface area and gut mucosal health, so this is a direct morphological improvement rather than an inferred one.
The 16S rRNA sequencing result is more specific than a generic "good bacteria up, bad bacteria down" summary, and it is worth reporting exactly: the Firmicutes phylum increased while the Bacteroidetes phylum slightly decreased. Metabolic profiling by LC/MS found 56 compounds significantly changed in positive ion mode and 99 in negative ion mode. KEGG pathway annotation pointed to adjustments in energy metabolism, amino acid metabolism, and nucleotide metabolism.
Notably, this study did not report short-chain fatty acid measurements, and it did not classify the bacterial shifts as beneficial or pathogenic. The authors' conclusion was measured: FVP could be developed as a dietary supplement for intestinal health promotion.
Gut bacteria changes from this kind of supplementation are generally not permanent. They persist as long as the fermentable substrate keeps arriving, which is how prebiotic effects work in general: the bacterial shift is driven by the food supply, and the food supply requires ongoing delivery.
Bacteroides, SCFAs, and the Study That Actually Connects Them
The claim most often attached to enoki and the gut is that it feeds Bacteroides and drives SCFA production. That claim has a real source, and it is Liang and colleagues (2022).[3]
Liang's team worked in immunosuppressed mice, which matters for interpretation: the comparison is against a suppressed model group, so the findings describe restoration toward normal rather than enhancement above baseline. Enoki polysaccharide increased thymus and spleen indices and improved thymus tissue structure. IL-2 and IL-4 rose significantly while IL-6 and TNF-α fell significantly. Serum acid phosphatase, lactate dehydrogenase, and total antioxidant capacity all increased, and in the liver, superoxide dismutase and catalase rose while malondialdehyde fell.
On the gut side, the study found that enoki polysaccharide increased the overall abundance and improved the structure of intestinal flora. Specifically, SCFA content increased, and so did the relative abundance of the SCFA producers Bacteroides and Alloprevotella, while Lachnospiraceae groups decreased.
This is the strongest single piece of evidence for the gut-mediated pathway, because SCFA output, SCFA-producing bacteria, and systemic immune organ measures all moved in the same animals in the same experiment. But two caveats belong with it. First, the SCFA finding is directional: total SCFA content increased. Neither this study nor any of the others reviewed here quantified how much propionate or acetate specifically changed in response to enoki polysaccharide. Any percentage figure attached to those two SCFAs and this literature should be treated as unsupported. Second, the cytokine direction here (IL-6 and TNF-α down) is the opposite of what Ye 2020 saw in isolated macrophages (IL-6 and TNF-α up). That is not necessarily a contradiction, because a suppressed animal being normalized and a cultured macrophage being stimulated are different situations, but it does mean enoki polysaccharide cannot be described simply as "immune boosting."
For the broader gut bacteria composition literature, including data on Akkermansia, Bifidobacterium, and Lactobacillus from other studies, the companion article Enoki and Gut Bacteria Composition: Research Review covers those findings in depth.
The One Experiment Using Human Gut Bacteria
Su and colleagues (2023) took a different approach: instead of feeding animals, they fermented enoki polysaccharide in vitro using human fecal inoculum.[4] The polysaccharide they characterized consisted mainly of glucose, mannose, xylose, fucose, and galactose. 16S rRNA sequencing assessed the microbiota response, and untargeted LC-MS metabolomics profiled what the fermentation produced.
The bacterial result: enoki polysaccharide increased the relative abundance of Bifidobacteriaceae and Bacteroidaceae, and markedly decreased Lachnospiraceae and Enterococcaceae. The metabolite result was not what a reader primed on SCFA stories would expect. The differential metabolites mainly involved glycerophospholipid metabolism, linoleic acid metabolism, and the synthesis of unsaturated fatty acids. The study did not report short-chain fatty acid quantification.
This is the closest thing to human data in the set, and it should be weighted accordingly: human gut bacteria, but in a flask. An in vitro fermentation has no host, no immune system, no absorption, and no gut transit. It tells you what human colonic bacteria can do with the substrate, not what happens in a person who eats it.
Same Lineage · Different Directions
Enoki and the Bacteroidetes Question
Three studies report movement in the same bacterial lineage — at three different taxonomic ranks, in three different systems — and they do not agree on direction. This is why “enoki feeds Bacteroides” overstates what the literature shows.
Phylum
Bacteroidetes
Healthy mice, 28-day feed
Hao et al., 2021 · Ref 2
Family
Bacteroidaceae
Human stool, in vitro fermentation
Su et al., 2023 · Ref 4
Genus
Bacteroides
Immunosuppressed mice
Liang et al., 2022 · Ref 3
These are nested ranks — Bacteroides sits inside Bacteroidaceae, which sits inside Bacteroidetes — so a phylum can fall while a member genus rises, and the three results are not strictly contradictory. But with different polysaccharide preparations and different host states in play, the taxonomic response to enoki is not yet consistent.
Source: Hao et al. (2021, gut health); Liang et al. (2022); Su et al. (2023)
Where the Studies Disagree
Reading these four studies together surfaces a genuine inconsistency that a tidier summary would hide. Hao 2021 found the Bacteroidetes phylum slightly decreased in mice. Liang 2022 found the genus Bacteroides increased in mice. Su 2023 found the family Bacteroidaceae increased in human fecal fermentation.
These are not strictly the same measurement. Bacteroidetes is a phylum, Bacteroidaceae is a family within it, and Bacteroides is a genus within that family, so a phylum can move one way while a member genus moves the other. The models also differ: healthy mice, immunosuppressed mice, and a flask of human stool bacteria. Different polysaccharide preparations were used in each study, and structure drives which bacteria can ferment a polysaccharide.
Still, the honest reading is that the taxonomic response to enoki polysaccharide is not yet consistent across preparations and models. The reliable common thread is narrower than "enoki feeds Bacteroides": across studies, enoki polysaccharide reaches the colon, is fermented there, changes which bacteria dominate, and in the two studies that measured them, increases short-chain fatty acids.
Beyond the Gut: Signals in the Spleen and Heart
Liang 2022 also used proteomics to examine what changed in tissue outside the intestine.[3] The analysis implicated pathways including immune disease signaling, transport and catabolism, phagosomes, and influenza A, and highlighted two regulated immune-related proteins: transferrin receptor protein 1 (TFRC) and radical S-adenosyl methionine domain-containing protein 2 (RSAD2). Combined with the increased spleen and thymus indices, this indicates changes registering in systemic immune organs, not only in the gut.
A second 2021 study from the same research group extends the point in an unexpected direction.[5] Hao and colleagues examined enoki polysaccharide's effects on intestinal microbiota, the immune repertoire, and the heart transcriptome in mice. Alongside regulating colonic microbiota abundance, the polysaccharide altered T-cell receptor gene usage: the usage frequency of TRBV1, TRBJ1-6, and TRBJ1-5 changed significantly, and 41 V-J pairs differed after treatment. In heart tissue, 525 genes and 1,587 mRNAs changed significantly, with upregulated transcripts enriched in pathways including tight junction, adherens junction, mTOR, insulin signaling, and TNF signaling.
Shifting the T-cell receptor repertoire is a more fundamental immune readout than a cytokine measurement, because the repertoire describes the diversity of antigens the immune system is equipped to recognize. What these two studies establish is that oral enoki polysaccharide is associated with measurable molecular change in tissues far from the gut. What they do not establish is the route. Neither study traced a specific gut-derived molecule to a specific remote effect, so "the SCFAs did it" remains a reasonable hypothesis rather than a demonstrated mechanism.
What This Evidence Does and Doesn't Resolve
Taken together, the five studies support a coherent picture. Enoki polysaccharides survive digestion and reach the colon. Colonic bacteria ferment them, and the bacterial community composition shifts (Ye 2020; Hao 2021; Liang 2022; Su 2023). In the two studies that measured SCFAs, output rose: butyric and isobutyric acid in rat caecum (Ye 2020) and total SCFA content in mice, alongside more SCFA-producing bacteria (Liang 2022). Gut structure improved in mice (Hao 2021). Immune and molecular changes were detectable in the spleen, thymus, and heart (Liang 2022; Hao 2021).
What none of it establishes is human relevance. Four of the five studies used mice or rats under controlled supplementation. The fifth used human bacteria in a flask, with no host attached. Polysaccharide doses were controlled amounts of purified, structurally characterized fractions, and they do not map onto a serving of enoki mushrooms in a mixed diet. The polysaccharide preparations differed between studies, which is a plausible source of the taxonomic disagreements described above.
No human feeding study has measured gut microbiota changes before and after regular enoki consumption. No human trial has measured SCFA production or immune markers in response to enoki polysaccharide supplementation. The mechanism is detailed and directionally consistent on its central points; the human dose-to-immune-response relationship is unknown. This article describes research findings and is not medical advice. Anyone considering mushroom supplements for an immune or gastrointestinal condition, particularly while immunosuppressed or on immune-modulating medication, should talk to a physician first.
The Bottom Line
Five preclinical studies from 2020 to 2023 trace how Flammulina velutipes polysaccharides may act on immunity through the gut: the polysaccharides reach the colon, gut bacteria ferment them, community composition shifts, and short-chain fatty acid output rises in the two studies that measured it. Molecular changes were detected in the spleen, thymus, and heart, and one study showed shifts in T-cell receptor gene usage. The studies disagree on the direction of Bacteroidetes-lineage bacteria, and no study has quantified propionate or acetate changes. Four studies used rodents and one used human stool bacteria in vitro; no human clinical trial has tested enoki polysaccharides for gut-immune endpoints.
Frequently Asked Questions
Sources & References
- 1RTHM-01306·Ye, Jufeng et al. (2020). “A novel polysaccharide isolated from Flammulina velutipes, characterization, macrophage immunomodulatory activities and its impact on gut microbiota in rats..” Journal of animal physiology and animal nutrition.Study breakdown →PubMed →↩
- 2RTHM-01363·Hao, Yuting et al. (2021). “Flammulina velutipes polysaccharide improves C57BL/6 mice gut health through regulation of intestine microbial metabolic activity..” International journal of biological macromolecules.Study breakdown →PubMed →↩
- 3RTHM-01567·Liang, Qiongxin et al. (2022). “The Effect of Flammulina velutipes Polysaccharide on Immunization Analyzed by Intestinal Flora and Proteomics..” Frontiers in nutrition.Study breakdown →PubMed →↩
- 4RTHM-01793·Su, Anxiang et al. (2023). “Effects of Flammulina velutipes polysaccharides on gut microbiota composition and metabolism in vitro fermentation..” Food science and biotechnology.Study breakdown →PubMed →↩
- 5RTHM-01362·Hao, Yuting et al. (2021). “The biological regulatory activities of Flammulina velutipes polysaccharide in mice intestinal microbiota, immune repertoire and heart transcriptome..” International journal of biological macromolecules.Study breakdown →PubMed →↩